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Abstract: The remarkable number of new molecular entities approved per year as parenteral drugs,
such as biologics and complex active pharmaceutical ingredients, calls for innovative and tunable
drug delivery systems. Besides making these classes of drugs available in the body, injectable depot
formulations o↵er the unique advantage in the parenteral world of reducing the number of required
injections, thus increasing e↵ectiveness as well as patient compliance. To date, a plethora of excipients
has been proposed to formulate depot systems, and among those, lipids stand out due to their unique
biocompatibility properties and safety profile. Looking at the several long-acting drug delivery
systems based on lipids designed so far, a legitimate question may arise: How far away are we from
an ideal depot formulation? Here, we review sustained release lipid-based platforms developed in the
last 5 years, namely oil-based solutions, liposomal systems, in situ forming systems, solid particles,
and implants, and we critically discuss the requirements for an ideal depot formulation with respect
to the used excipients, biocompatibility, and the challenges presented by the manufacturing process.
Finally, we delve into lights and shadows originating from the current setups of in vitro release assays
developed with the aim of assessing the translational potential of depot injectables.
Keywords: injectable lipid depot; long-acting drug delivery system; oil-based solutions; liposomes;
in situ forming systems; implants; solid particles
1. Introduction
Medication non-compliance is a dreadful bottleneck for successful treatment outcomes in a
multitude of diseases. Among the factors threatening patient adherence, a high number of daily doses,
the duration of the condition (acute versus chronic), and the transition to chronification as well as
adverse side e↵ects pose severe challenges [1]. The World Health Organization (WHO) has reported
that in countries in the Global North the concordance to long-term therapies stands at about 50% [2].
The administration of properly designed long-acting formulations reduces the frequency of required
doses needed to achieve and maintain therapeutic e cacy, improving patient compliance and overall
reducing unwanted side e↵ects. Furthermore, depot formulations could be particularly beneficial
for classes of patients that are unable to adhere to treatment regimens, such as those su↵ering from
psychiatric disorders [3].
The remarkable number of yearly approved new parenteral molecular entities, including antibodies,
proteins, and peptides, but also small molecules characterized either by instability in the gastrointestinal
tract or high first-pass metabolism, encourages the design of more versatile drug delivery technologies.
This review aims at providing a synopsis of the most recently developed platforms (over the last 5
years) with lipids as a primary excipient, emphasizing systems with high translational potential and
o↵ering a critical perspective on non-standardized in vitro release assays.
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Despite the massive scientific output in this field, to date no consensus in the terminology has
been reached. A plethora of delivery technologies for injectable depots has been developed over the
last years, as shown in Figure 1, but inconsistent terms to describe the concept of long-term release
are routinely employed: “long-acting injectable”, “controlled release”, “sustained release”, “extended
release”, or “depot” formulations. In terms of the duration of the release, questions arise as to when
a drug delivery system could be considered “sustained” or “prolonged”, or when a formulation
could be denominated as a “depot”. The United States Pharmacopeia (USP) describes “extended
release”, a synonym for “prolonged” and “sustained release”, as a deliberate modification to protract
the release rate of an active pharmaceutical ingredient (API) in comparison to an immediate release
dosage form [4]. In the European Pharmacopoeia (Ph. Eur.), prolonged release and extended release
are used as synonyms and are defined as characterized by a slower release of the API with respect to a
conventional release dosage form administered by the same route [5]. It is still unclear whether even a
prolongation of a few hours could be considered as a sustained release or if only a protraction expressed
in days is noteworthy. Although a handful of examples of depot injectables able to extend release only
for few hours are mentioned in the present review, the majority of technologies we considered provide
a sustained release of the API in a timespan of days at least.
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Figure 1. Number of publications over the years using as search terms “long acting injectable”,
“long acting parenteral”, “long acting depot”, “depot formulation”, “sustained release parenteral”, or
“controlled release parenteral” via a PubMed inquiry by year [6].
2. The Ideal Depot Delivery System
An ideal depot formulation delivers the drug at a tunable, predetermined rate within the
therapeutic range for a specified period, ideally for as long as possible for the treatment of chronic
diseases [7]. Release can take place directly at the site of action for a local treatment or at a systemic
level, thus reducing the adverse side e↵ects of the drug to a minimum [8]. Furthermore, the ideal
delivery system undergoes full biodegradation at a rate consistent with the desired release rate of
the API, and the matrix biocompatibility does not induce adverse reactions at the site of injection [9].
During the development of a novel delivery system, an adequate shelf life has to be considered in
order to enable the desired release profile and longevity. During storage, the loaded drug does not leak
from the vehicle in order to avert a burst release after application and to ensure that the entire dose
is released over the desired time range. Interactions of the drug with the delivery systems could be
exploited to improve stability and to reduce leakage of drug, although it has to be ensured that such a
stabilization strategy does not interfere with the desired release profile [10].
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In practice, not all requirements could be fulfilled in a universal delivery platform; nevertheless,
existing lipid-based systems are continuously being improved to meet as many conditions as possible,
as highlighted in the following sections.
2.1. Excipients for Formulating Depots
Two major classes of chemical compounds are used to create drug delivery systems: polymers
and lipids [11]. Despite the fact that both serve the same purpose—encapsulating drugs for
depot formulations—they di↵er in their fundamental properties like chemical structure, solubility,
or biodegradability and biocompatibility. The focus of this review is exclusively on depot formulations
based on lipids, although hybrid systems combining the benefits of lipid and polymeric excipients will
also be discussed. For more details about polymeric drug delivery systems we refer the readers to
dedicated comprehensive recent reviews [12,13].
Lipids are defined as hydrophobic or amphiphilic small molecules originating entirely or in part
by carbanion-based condensations of thioesters and/or by carbocation-based condensations, and are
classified by LIPID MAPS® into eight categories shown in Table 1 [14,15].
Table 1. Classification of lipids according LIPID MAPS with examples of subgroups [15,16].
Category Subgroup Examples
Fatty acyls Fatty esters, fatty amides, fatty acyl glycosides
Glycerolipids Mono-, di-, triradylglycerols
Glycerophospholipids Glycerophosphocholines, -serines, -glycerols, -inositols
Sphingolipids Sphingoid bases, ceramides, phosphosphingolipids
Sterol Lipids Sterols, steroids, secosteroids, bile acids, and derivatives
Prenol Lipids Isoprenoids, quinones and hydroquinones, polyprenols
Saccharolipids Acylaminosugars, acylaminosugar glycans, acyltrehaloses
Polyketides Flavonoids, macrolides, linear or aromatic polyketides
2.2. Parenteral Administration Routes for Depot Injectables
Administering depot formulations parenterally is a recommended choice for drugs which undergo
substantial first-pass metabolism or that are characterized by low oral bioavailability. Typically,
the subcutaneous (s.c.) and intramuscular (i.m.) routes are preferred to achieve a systemic e↵ect.
When local treatment is sought, intraarticular or intraocular injections are also considered viable options
depending on the condition to address. The absorption, distribution, metabolism, and elimination of a
drug strongly rely on the characteristics of the biological environment. Opting for a specific site of
administration thus represents a strategy to modulate the drug release kinetics. As the blood perfusion
in the s.c. tissue is lower than in the muscles, a s.c. injection will result in a delayed absorption of the
drug with respect to an i.m. injection [17]. Targeted, localized drug delivery could be beneficial for
diseases a↵ecting only a small, distinct area of the body, resulting in a high local drug concentration
but a low systemic concentration, thus reducing systemic side e↵ects and overall toxicity. Moreover,
di↵usion barriers and drug metabolism could be circumvented.
S.c. injections are the most-often used parenteral administration route due the possibility of
self-injection by the patients, but the administered volume is limited. The administration of volumes
larger than 1.5 to 2 mL usually requires multiple injections to minimize the risk of considerably high
pain upon injection. For example, it has been shown that incrementing the injected volume from 0.8 to
2.25 mL resulted in an increase of the perceived pain about 1.7-fold [18,19]. The choice of the most
suitable drug delivery system has to be carefully considered; the potency of the drug and the dose on
the one hand and the encapsulation capacity of the delivery system on the other play a decisive role in
this selection. Although it has been reported that the used bu↵ers (pH, osmolarity) in the formulations
could influence the pain upon injection [18], no correlation between di↵erent lipids and the induction
of pain has been investigated so far.
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Sterilization of the final product is mandatory for this route of application; however,
(phospho)lipids are sensitive to high temperatures, and sterilization processes such as steam sterilization
or dry heat sterilization may cause oxidation and hydrolysis of the (phospho)lipids, resulting in a
destabilization of the delivery system. Sterilization of lipid-based products might thus be achieved
via gamma-irradiation, sterile filtration (only for colloidal systems with a size below 200 nm), or via
production under aseptic conditions [20].
2.3. Biocompatibility
Host response to the depot formulations, including foreign body reactions or fibrous encapsulation,
plays a pivotal role in the choice of materials for long-acting formulations. The extent is dependent on
the size, shape, and composition of the drug delivery system on the one hand and on the targeted tissue
or organ on the other [21]. An initial acute inflammatory response is triggered after every injection due
to the minimal injury of the connective tissue. Released leachables or degradation products from the
delivery system could promote this inflammatory response and could turn the acute inflammation
into chronic inflammation if the stimuli are persistent [22]. Ultimately, a collagenous fibrous capsule
of typically 50–200 µm thickness can be built as reaction of the immune system to the foreign object,
especially for solid implants or in situ forming systems. This creates an additional di↵usion barrier
influencing drug release [23–25].
Being able to predict biocompatibility is of paramount interest for a successful delivery system:
early toxicity screenings could be performed using in vitro tests but for the assessment of the
multiple tissue reactions, in vivo studies combining pharmacokinetic and pharmacodynamic e↵ects
are also required. Besides quantifying the plasma concentrations of inflammatory cytokines and the
macro- and microscopical inspection of the surrounded tissue, a cage implant system could be used.
This system enables the characterization of degradation products of the drug delivery system as well
the inflammatory exudates in the surrounded tissue. Regrettably, the inflammatory reactions from the
cage itself could represent an insidious Trojan horse [26–28].
Lipids are characterized by an outstanding biocompatibility and safety profile due to their
occurrence throughout the living world and the biodegradability in the human body induced by
lipases [29,30]. For liposomes, the lipids used for the production of multivesicular liposomes did not
induce any foreign body reaction [31,32].
3. Oil-Based Solutions
Oily solutions containing a dissolved or suspended drug were first introduced in the 1950s and are
hence the oldest approach proposed for injectable depots. They were traditionally used for antipsychotic
drugs or hormones, and several di↵erent products became available over the decades, including Haldol
Decanoate, Depo-Testosterone, Invega Sustenna, or Depo-Provera, to name a few that are still on the
market [33,34]. With the aim of providing a more pronounced lipophilicity to extend drug release,
highly hydrophobic esters were usually conjugated to first-generation antipsychotics. The drugs
are dissolved in pharmaceutical oils like sesame seed oil or middle-chain triglycerides. Upon i.m.
injection, drug transfer from the oil phase into the tissue fluid represents the main release-limiting
factor. Spreading of the oil solution along the muscle fibers can occur, increasing the surface area and
therefore accelerating drug release [35,36]. Although this depot system has a favorable long-term
stability and can be prepared in a fast and uncomplicated manner with sterilization of the final product,
only lipophilic drugs can be included. Hydrophilic drugs have to be modified prior to insertion,
which limits the use of the system. In recent years almost no new approaches using dissolved drugs
in oily solutions have been reported, and the system is still traditionally used for antipsychotics
(Table 2). The concept of oil-based solutions has been further elaborated, and, in most cases, the drug
is encapsulated in a carrier and then dissolved in an oil phase (Figure 2).
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Table 2. Overview of oil-based drug delivery systems.
Principle Encapsulated Drug Release Time Range Advantages (+) and Disadvantages (–) Ref.
Classical oil-based solutions with dissolved drug
Oily solution
Paliperidone palmitate,
medroxy-progesterone,
haloperidol decanoate,
testosterone (in general
antipsychotics and
hormones
Up to several months,
in vivo
+ Fast and easy preparation
+ Long-term stability
+ Low viscosity, easy injection
– Only lipophilic drugs,
otherwise modification
– Spreading at injection site
[33,34]
Drug combined with second carrier in oil-based solutions
Microparticles in
oily solution Ondansetron
Hours, in vitro and
in vivo
+ Hydrophilic and hydrophobic
drugs, biomacromolecules
+ Low viscosity, easy injection
– Further preparation steps required
– System including drug must be soluble or
dispersible in oil
– Spreading at injection site
[40]
Proliposomal oil Ropivacaine Days, in vivo [41,42]
Solid dispersion in oil Ivermectin, toltrazuril(veterinary) Days, in vivo [38,43,44]
Nanoprecipitates in oil Tenofovir disoproxilfumarate Hours, in vitro [45]
Lyophilized liposomes
dispersed in oil
(DPX/DepoVax™)
Vaccines, antigens Weeks, in vivo [46,47]
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from the classical dissolved drugs in oil (a) to more advanced systems like solid dispersions (b),
proliposomes (c), or the Dep Vax/DPX system ( ). (a) Adapted from [37]; (b) Reprinted from [38],
with permission from Elsevier; (d) Adapted from [39].
A hybrid system based on methylcellulose microparticles suspe ed in corn oil was proposed
by Nguyen et al. [40]. The in vitro release of encapsulated ondansetron was prolonged up to 120 h,
and after s.c. injection into rats, the plasma concentration was maintained over 72 h with an enhanced
bioavailability. Lu et al. tried a similar approach based on a solid dispersion of ivermectin in
hydrogenated castor oil, demonstrating a prolonged release in v tro and a higher AUC (area under
the curve) and mean residenc time in rabbits [43,44]. Besides favorable pharmacokinetics, such an
approach proved to have a therapeutic potential, as proved by the elimination of a parasite infection
in rabbits treated with the iverm ctin depot. An advancement of this concept was attempted for
the development f a s art, stimulus-sensitive system: a micro-environmental pH-modifying solid
dispersion suspe ded in oils fo drugs with pH-dependent solubility o↵ering sustained release of
toltrazuril in vitro investigated over 72 h, with good biocompatibility [38]. This drug is only used in
veterinary medicine, but the system might be applicable for other drugs used in humans. With the
aim of preventing moisture contact to hydrophilic APIs du ing formulation, a complete anhydrous
nanoprecipitation method for the hydrophilic drug disoproxil fumarate was recently reported by
Hobson and coworkers [45]. Th nanoprecipitates were subs quently dis er d in di↵erent oils
intended for i.m. injection. In vitro release studies using a dialysis method were carried out only
over 6 h, making it hardly possible to estimate the depot e↵ect. An additional drawback of the
system is represented by the use of organic solvents like dichloromethane and methanol in the
manufacturing process.
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The above-mentioned approach was revisited by the company PainReform Ltd. (Herzeliya, Israel):
phospholipids, co-dissolved in an oily solution with a drug of choice, created a proliposomal oil,
thus transforming a classical drug delivery system in a pro-formulation system [41,42]. Upon injection
and contact with body fluids the amphiphilic phospholipid molecules self-assemble into drug-loaded
multilamellar liposomes in the micron range. Following s.c. injection in pigs, a proliposomal oil
formulated with ropivacaine showed a 5-fold increase in half-life and local anesthesia e↵ect, while in
human volunteers the formulation of ropivacaine in a proliposomal oil resulted in a 2- to 3-fold increase
in anesthetic e↵ect over plain ropivacaine. Combining the advantages of liposomes with an oil-based
solution represented the core idea of a vaccine delivery platform with sustained immunological activity.
The system, called DPX (formerly DepoVax™), is based on lyophilized liposomes encapsulating
antigens or nucleic acids which are dispersed in oil diluents [48]. In comparison to regularly used
emulsions, the system does not require the use of emulsifiers, does not support a passive release in vitro,
and retains the antigens at the site of injection in vivo. DPX facilitated in vivo the development and
persistence of T cells and provided a better control of tumor growth [46]. Recently, Weir and coworkers
used DPX for an anthrax vaccine formulation to reduce the current multidose vaccination plan (five
injections over 12 months combined with an annual booster) to a single injection, obtaining 100%
protection against anthrax in rabbits and non-human primates [47]. Di↵erent clinical trials in early or
late phase 2 are ongoing for the treatment of ovarian cancer and lymphoma using immunotherapy [49].
Although the preparation of oily solutions might be easy and fast, these depot systems have the
disadvantage of spreading at the site of injection because of their low viscosity. Consequently, semisolid
formulations with a higher viscosity or liquid in situ solidifying systems were developed (see Section 5,
Semi-Solid Preparations and in Situ Forming systems). The latter approach especially combines the
advantages of easy administration and the formation of a physical depot in vivo (vide infra).
4. Liposomal Systems
First described in 1961, liposomes are spherical vesicles composed of a phospholipid bilayer
enclosing an aqueous core. In addition to phospholipids, other lipids like cholesterol can be incorporated
into the bilayer, while the surface of the vesicles can be modified with sterically stabilizing polymers
and/or targeting ligands [50]. Liposomes are traditionally used as a drug delivery system to increase
the solubility of hydrophobic drugs, reduce their toxicity, prolong the circulation in the blood, or enable
active targeting [51]. Alone or in combination with other excipients (hybrid systems), liposomes may
provide a sustained release of the encapsulated drugs [52–54]. The versatile applicability of the system
is depicted in Figure 3 and described in Table 3.Pharmaceutics 2020 12 x of 0
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The release of drugs encapsulated in liposomes, and with it the possibility to achieve a
depot e↵ect, is mainly dependent on the di↵usion of the drugs across the bilayer. By generating
liposomal aggregates, the di↵usion of the drug into the surrounding can be mitigated,
as recently proposed by our group [55]. Long-acting drug delivery systems could indeed
be generated in situ, controlling the aggregation of liposomes formulated with negatively
charged phospholipids (NCPs) through the interaction with divalent cations. Various NCPs
were screened as function of their head groups and acyl chains for their suitability as sca↵old
for depot formulations and the system extensively characterized from a physico-chemical
viewpoint. Mixing liposomes formulated with either 1,2-dipalmitoyl-sn-glycero-3-phosphate (DPPA)
or 1,2-distearoyl-sn-glycero-3-phospho-(10-rac-glycerol) (DSPG) with physiologically compatible
concentrations of calcium and magnesium resulted in a rapid fusion-free aggregation, confirming the
pharmaceutical potential of intact liposomes as single composing units of the depot. Bupivacaine-loaded
liposomal aggregates are presently under evaluation in our laboratories as an analgesic platform
alternative to the current strategies for pain management.
Negatively charged phospholipids could be also used to form so-called cochleates, defined
as supramolecular assemblies of phospholipid bilayers which form spiral structures with divalent
cations [82]. Despite the thorough characterization conducted by Fahr and coworkers so far [83,84],
their clinical potential regarding their use as drug delivery system still needs to be investigated.
Drawing from this concept, Blazaki et al. induced aggregation of negatively charged liposomes
with protamine and encapsulated two di↵erent fluorescence dyes or the anti-inflammatory drug
flurbiprofen [59]. The in vitro release of the fluorescent dyes was sustained for more than 17 days,
whereas flurbiprofen showed a sustained release over only 120 h. Despite the increase in retention of
flurbiprofen in vivo in the posterior eye segment after intravitreal injection achieved with the aggregated
liposomes, the di↵erences with respect to the non-aggregated system were rather small. Seeking a
strategy aimed at avoiding repeated injections during emergency treatments such as cardiopulmonary
resuscitation, Schlich et al. described the use of adrenaline-loaded PEGylated liposomes [60]. One of
the reported challenges during the production process of this formulation was to prevent the oxidation
of adrenaline, which could ultimately be ensured by addition of an antioxidant while maintaining the
loading e ciency of the active loading method. The in vitro release of the API was investigated for
only 8 h (cumulative release of around 10%) in two di↵erent release setups, with neither reflecting the
complexity after intravenous injection. The authors did not address how this liposomal system could
be included in the treatment protocol for emergency situations in clinical practice.
Liposomes could not only act as a sustained drug delivery system, but the phospholipids
themselves could exert local, mechanical beneficial e↵ects in the management of osteoarthritis [62].
Distearoyl phosphatidylcholine (DSPC) liposomes encapsulating D-glucosamine sulphate combined
the anti-inflammatory e↵ects of the drug and the lubrication ability of the liposomal system in the
joint. A prolonged release over several days in vitro was achieved and the friction between a silica and
polystyrene surface in an atomic force microscopy setup reduced. The lubrication e↵ect of the liposomes
is attributed to a hydration layer around the phospholipid headgroups creating a ball-bearing-like
system. It is questionable whether the lubrication enhancing is a clinically relevant e↵ect, since, so far,
this has only been tested in instrumental setups or ex vivo using human cartilage [85,86].
A combination of fast and prolonged releasing liposomes was used by Christensen et al. as a
parenteral vaccine strategy able to generate a long-lasting intestinal immune response to prevent
enteric infections [61]. The fast releasing system comprised retinoic acid in PEGylated liposomes
to pre-condition the vaccine-draining lymph nodes. Cationic liposomes based on the surfactant
dimethyldioctadecylammonium bromide (DDA) and stabilized with the synthetic immunostimulator
trehalose 6,60-dibehenate (TDB) formed a depot at the site of injection and delivered over a prolonged
period of time the antigen. In vivo results confirmed this hypothesis and the combination of both
species induced an antigen-specific intestinal immunoglobulin A response after s.c. injection.
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Looking at the list of the liposomal drugs approved by the US Food and Drug Administration
(FDA), only three can be strictly considered sustained drug delivery systems: Exparel® (bupivacaine),
DepoDur® (morphine), and DepoCyte® (cytarabine). These three formulations share an important
aspect, that is, the same multivesicular liposomes technology, DepoFoam® [87,88]. Multivesicular
liposomes (MVLs), first described by Kim et al. 1983, are micron-sized vesicles containing numerous
internal aqueous compartments divided by non-concentric lipid bilayers, as shown in Figure 3c [89,90].
The production follows a two-step, water-in-oil-in-water double-emulsification process under aseptic
conditions [91]. In contrast to conventional liposomes, the use of a neutral lipid besides phospholipids
is mandatory to form this unique structure [89]. Several mechanisms that contribute to the release of
encapsulated drugs, like di↵usion, erosion, and reorganization of the compartments as well the used
phospholipids and neutral lipids have a major influence on the release profile [89,92]. While DepoDur
and DepoCyt were discontinued from the market in the United States or Europe, Exparel was
recently approved (2011) [87,88,93]. The research approaches aiming at exploring this technology
for the delivery of bupivacaine in new indications are proliferating [71,72,94]. Besides bupivacaine,
ropivacaine was considered as cargo for MVLs for prolonged-duration local anesthesia [65,66].
After successfully encapsulating small molecules, attention was drawn to the use of this delivery
system for biomacromolecules. MVLs loaded with bevacizumab were used for the treatment of
choroidal neovascularization, resulting in a prolonged intravitreal retention time of bevacizumab
and consequently in a reduced number of intraocular injections [58]. Becavizumab–MVLs turned
out to be superior to plain bevacizumab solution with respect to the e↵ective inhibition of the
thickness of the choroidal neovascularization lesion at 28 days after treatment. The MVLs showed
a prolonged release for 10 up to 13 days in vitro, mostly sustained for the formulation containing
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). Interestingly, a more extended depot e↵ect using
conventional liposomes was reported by Karumanchi et al. [63]. Bevacizumab was released in vitro
over 70 to 100 days out of conventional liposomes and over an even much longer time period using
stealth liposomes (150 to 200 days). Besides di↵erences in the in vitro drug release setup, the in vivo
experiments were designed di↵erently, and thus the results could not be compared directly. Karumanchi
et al. injected the conventional liposomes into the anterior segment of rabbit eyes and observed
therapeutic concentrations of bevacizumab over 22 weeks, as determined by non-invasive fluorescence
imaging after fluorescence tagging of the antibody. Bevacizumab–MVLs injected into rabbit eyes
showed therapeutic concentrations over the full 56 days of study duration after direct measurement
of the antibody concentration in vitreous and aqueous humor. The comparison of these two studies
underlines how critical the choice of the in vitro release setup is to compare results obtained from
di↵erent groups.
Although mostly hydrophilic drugs were encapsulated very e ciently owing to the large aqueous
compartments in the MVLs, various attempts were made to include hydrophobic drugs into this
system. Luo et al. encapsulated oleanolic acid, a pentacyclic triterpenoid, into the bilayer of the
MVLs and in vitro and in vivo showed a prolonged release and plasma concentrations superior to
free oleanolic acid, respectively [68,69]. A di↵erent approach to include a hydrophobic agent into
the MVL was pursued by Vafaei and coworkers using cyclodextrins [70]. The lipophilic model
drug fluocinolone acetonide was encapsulated into di↵erent cyclodextrin inclusion complexes and
subsequently incorporated into MVLs by reverse-phase evaporation. The in vitro drug release was
sustained up to 180 h depending on the used cyclodextrin.
To summarize, MVLs are an all-round platform for prolonged drug delivery. A high encapsulation
e ciency for hydrophilic drugs can be achieved due to their relatively high water content (aqueous:
lipid ratio 95:5). The nonconcentric bilayer geometry increases the stability of the system and reduces a
burst release, while the depot e↵ect itself relies on reduced clearance, an aftermath of the micron-range
size of the vesicles [87,91]. Despite the superb clinical success, the drawbacks of this system, mainly with
respect to the manufacturing procedure, should not be overlooked. The double-emulsification process
requires the use of organic solvents and needs to be performed entirely under aseptic conditions [89,90].
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At the other end of the scale, conventional small and large unilamellar liposomes are still being
intensively investigated and show tremendous potential for depot systems, especially in a hybrid
modality, in combination with other biocompatible materials like gel matrices to form liposomes
in gel, which are favorable for local drug release due to the increased viscosity of the system.
The biodegradable hydrogel poly(lactic-co-glycolic acid)–polyethylene glycol–poly(lactic-co-glycolic
acid) (PLGA–PEG–PLGA) was proposed as matrix to embed liposomal doxorubicin, thus enabling the
taming of the burst release typical of PLGA systems in favor of a smoother, prolonged release [76].
For the first 12 h the hybrid composite depot outperformed the pristine doxorubicin in hydrogel,
while the in vitro sustained profile of the liposomal gel was maintained for over 11 days; furthermore,
tumor growth was significantly reduced in a breast cancer model in mice, and the known cardiotoxicity
of doxorubicin was reduced. The same approach of liposomes in gel but using a Pluronic® (poloxamer)
hydrogel was tried by Fu and colleagues, who encapsulated doxorubicin and paclitaxel for the treatment
of hepatocellular carcinoma [73]. After local injection the system inhibited the tumor growth in vivo
significantly and reduced the toxicity of the drugs.
Coating the liposomal surface with polymers could represent an alternative strategy to
extend drug release over time, as proposed by Ravar and coworkers [80]. Hyaluronic acid
was used produce hybrid polymer-lipid vesicles via electrostatic coating upon titration of 1,2-
dioleoyl-3-trimethylammonium-propan (DOTAP)-based large unilamellar liposomes encapsulating
paclitaxel. Although the in vitro release of paclitaxel followed over 40 h was not substantially prolonged
in comparison to hyaluronic acid-free plain liposomes, the tumor growth in vivo in 4T1-tumor bearing
mice intravenously injected with the depot system was reduced by about 10-fold with respect to the
ones treated with a commercial paclitaxel solution, and the overall survival of the mice increased by
60% over 20 days. The addition of more than one polymer can lead to the formation of layer-by-layer
particles, also called capsosomes, arising from electrostatic interactions [56]. The capsosomes were
formed by covering a cationic liposomal core layer-by-layer with hyaluronic acid and chitosan, topped
with small sized liposomes and hyaluronic acid. Although it seems a promising approach to sustain
the drug release using several layers as a di↵usion barrier, investigations about the encapsulation of
drugs and their release are missing. A completely di↵erent strategy was adopted by Nascimento Vieira
et al., who encapsulated a drug into cycodextrins and included this complex into liposomes to improve
the encapsulation e cacy, prolong the release, and enhance the biological activity [81]. The ternary
drug delivery system containing ropivacaine sustained the release in vitro up to 8 h while the cell
toxicity of ropivacaine was reduced. Furthermore, the in vivo sensory block of the local anesthetic
was prolonged 1.7 times in comparison to the drug solution. These examples demonstrate the variety
of liposomal hybrid systems acting as an alternative to MVLs, and their clinical relevance should be
further investigated.
5. Semi-Solid Preparations and In Situ Forming Systems
Injectable in situ forming gels are an attractive way to deliver drugs due to their easy handling
prior to and during administration. The depot can be conveniently generated upon contact with
body fluids or when the physiological temperature is reached upon injection. A brief overview of the
reported technologies is given in Figure 4 and summarized in Table 4.
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Table 4. Overview of semisolid and in situ forming drug delivery systems.
Principle Encapsulated Drug Release Time Range Adva tages (+) and Disadvantages (–) Ref.
Phospholipid-based
phase separation gel
(PPSG)
Ropivacaine, pitavastatin,
5-fluoro racil, paclitaxel,
doxorubicin,
bromo-tetrandrine,
dabigatran etexilate,
exenatide, leuprolide,
octreotide, insulin,
incomplete Freund’s
adjuvant
Days to weeks, in vitro
and in vivo
+ Hydrophilic and lipophilic drugs,
biomacromolecules, but
– Drug needs to be soluble in ethanol
+ Fast and easy preparation and
upscale possibilities
+ Low viscosity of precursor solution
for easy injection
+ No initial burst release
– Use of ethanol could cause
side e↵ects
[95,100–110]
Vesicular
phospholipid gels
Interferon-beta-1b,
granulocyte-colony
stimulating factor, exenatide,
FKBP51 antagonist
Days to weeks in vitro
and in vivo
+ Hydrophilic and lipophilic
drugs, biomacromolecules
+ Solvent-free manufacturing
+ Long-term storage form
for liposomes
– Semisolid behavior, high forces for
injection required
– Sterilization problematic, aseptic
production required
[111–115]
Phospholipid gel
depo (PG Depot™)
Small molecules, proteins,
peptides Days
+ Hydr philic and lipophilic
drugs, biomacromolecules
+ Low viscosity even with high
phospholipid mount
+ Aqueous system with optional
removal of water
– Detailed information
is patent-protected
[116,117]
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Table 4. Cont.
Principle Encapsulated Drug Release Time Range Advantages (+) and Disadvantages (–) Ref.
Liquid crystalline
phases (cubosomes,
hexosomes),
FluidCrystal
®
,
hybrid systems
Bufalin, bupivacaine,
minocycline, indomethacin,
finasteride, doxorubicin,
buprenorphine (Buvidal®,
Brixadi®), sinomenine,
docetaxel, leuprolide,
octreotide, setmelanotide,
Huperzine A, VEGF siRNA
(combined with
polyethylene-imine),
Days to weeks in vitro
and in vivo
+ Hydrophilic and lipophilic drugs,
biomacromolecules, but
– Size of water channels need to be
altered for release
of macromolecules
– High water content could induce
burst release of hydrophilic drugs
– High viscosity of cubic and
hexagonal phase requires high
injection forces, but
+ Dilution to cubosomes and
hexosomes or use of water-free
precursor solutions
decrease viscosity
+ Choice of (phospho)lipids can
control final properties
– Contact with body fluids could
change crystal structure, but
+ Precursor solutions use the
transformation to liquid crystal
systems upon contact with
body fluids
– Small changes in production can
lead to di↵erent crystal structures
– Highly controlled production
process required
[98,118–132]
Nanoemulsion Bupivacaine Hours, in vitro andin vivo
+ Hydrophilic and lipophilic drugs
+ Fast and easy preparation
– Addition of polymeric surfactants
to stabilize the system could
induce toxicity
– Depot e↵ect rather small
[133]
Organogel
Candesartan cilexetil,
risperidone
Days in vitro and
in vivo
– Only lipophilic drugs possible
+ Easy preparation
– High viscosity complicates injection
– Use of organogelators could
increase toxicity
[134,135]
Phospholipid-based phase separation gels (PPSG) combine simple manufacturing with the use of
excipients known for their high biocompatibility and of solvents with low toxicity such as ethanol,
soybean oil, and medium-chain triglycerides. By dissolving the phospholipids in ethanol and neutral
oil mixtures and subsequently adding the drug of choice, a straightforward upscale can be envisaged,
while a sterilization by sterile filtration can be performed to ensure the production of a product suitable
for parenteral administration [100,104]. After s.c. injection and contact with the body fluids, a sol–gel
transformation occurs due to the di↵usion and exchange of ethanol out and tissue fluids into the gel,
initiating a phase transition of the phospholipids and resulting in an increase in the viscosity in a range
from 10- to 106-fold [95,103,104,110]. The remarkably higher phospholipid concentrations (up to 70%) of
PPSGs with respect to organogels or vesicular phospholipid gels is responsible for the low viscosity and
negligible initial burst release after administration [104]. The existence of the gel over a long time period
was proven by fluorescence imaging or harvesting of the depot [95,100,103,105]. Encapsulating small
molecules could prolong the release in vitro for several days, as shown by Li et al., when incorporating
ropivacaine into PPSG [95]. The initial burst observed for the local anesthetic solution after s.c. injection
into rats was reduced using the depot system and the nerve blockade in guinea pigs lasted three
times longer. The in vivo drug release or the therapeutic e↵ect for biomacromolecules was observed
for up to weeks, as in the case of exenatide released over 3 weeks [106], and leuprolide acetate and
octreotide acetate both released for over 4 weeks [107,108]. The administration of an antigen using this
delivery system led to a persistent immune response and immunologic memory, showing the potential
of PPSG as new vaccine adjuvant [105]. In general, foreign body reactions and tissue responses are
related to the ethanol content and are reduced by increasing the phospholipid content, while the
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inflammatory responses are low and disappear with depot degradation [100,103,105]. Using this depot
system, the toxicity and side e↵ects of the drug itself are reduced while showing the same or even
better therapeutic e↵ect [101,102,105]. PPSGs are fully biodegradable but only limited information is
available about the detailed degradation pathway. The formation of small vesicles at the edges and
their release from the main gel are assumed [100].
In comparison to the PPSG, vesicular phospholipid gels (VPGs) comprise phospholipids not in
solution, but rather as tightly packed vesicles and lamellar structures. This minimizes the surrounding
aqueous phase and leads to the typical semisolid behavior mediated by the steric interactions of the
vesicles without the need for additional viscosity enhancers. Dilution of the system after injection results
in the formation of small unilamellar vesicles, as recently reviewed [136]. The inner structure of the
densely packed vesicles causes a relatively high viscosity and it might be di cult or even impossible to
inject them. A promising needle-free injection approach for VPGs to overcome this hurdle was proposed
by Breitsamer et al., but a clinical validation is to date still missing [137]. VPGS have been intensively
investigated for the delivery of proteins and peptides [111–113]; for example, exenatide–VPGs showed
a release in vivo over 11 days, and the hypoglycemic e↵ect in diabetic rats lasted for 10 days upon
injection [114].
Latitude Pharmaceuticals Inc. o↵ers a phospholipid gel depot (PG Depot) that contains between
20% and 80% phospholipids nano-dispersed in water and can be easily injected through a 25 G needle.
A variety of drugs can be loaded in this system, from small molecules to proteins and peptides. In a
first step a phospholipid nanodispersion with a high-water content is produced and a gel phase is
subsequently obtained by removing water in a second step. The depot e↵ect could be adjusted from 1
to 7 days [116,117,138].
Lyotropic liquid phases are characterized by a self-assembly of amphiphilic lipids to di↵erent
lamellar, hexagonal, or cubic phases or a reversed micellar cubic phase. The relatively high viscosity
of the systems is an advantage for topical administrations but is not beneficial for their injectability.
Consequently, the cubic or hexagonal phase can be dispersed in aqueous solutions forming cubic
(“cubosomes”) or hexagonal nanoparticles (“hexosomes”) with an intact inner liquid crystalline
structure and larger surface area but a lower viscosity [139]. An alternative strategy to improve
their injectability is based on the use of a lower amount of viscous precursor (with a low amount of
water): body fluids are taken up in vivo upon injection, resulting in the formation of a viscous depot
system in situ [118,123,125]. A comprehensive overview about the detailed inner structure, preparation
methods, and applications has been given in two recent reviews [140,141]. Narrow-sized water
channels in the liquid crystal structure cause the sustained release behavior of low-molecular-weight
drugs but might inhibit the release of molecules with higher molecular weight and therefore demand
the addition of hydration-modulating agents [142]. The in vitro duration of action of the depot e↵ect
ranges from several days for bufalin [125], to 10 days for minocycline [126], or up to one month for
leuprolide acetate [98], and can be easily tuned by adjusting the ratios of the used compounds [121].
A novel non-viral gene delivery system was designed by Borgheti-Cardoso et al., combining liquid
crystals with polyethylenimine (PEI) to complex siRNA (small interfering RNA) [129]. The release of
siRNA was maintained over 7 days in vitro, while in vivo the in situ formed gels were degraded over
30 days, inducing only a mild inflammatory response. The siRNA was released in a complex with
PEI, which protects the siRNA against degradation, but experimental data about the gene silencing
e ciencies of the released siRNA are missing to date. Overall, the groups developing liquid crystalline
phases as injectable depots have focused mainly on the characterization of the systems using methods
like small angle X-ray scattering, electron or polarized light microscopy, rheology, and in vitro drug
release studies [98,124,143]. Besides measuring drug plasma concentrations, little attention has been
paid to additional in vivo characterization like the fate of the depot after injection, possible local side
e↵ects, and biocompatibility or the pharmacological e↵ect.
The only liquid crystalline system that has reached clinical studies is based on the FluidCrystal®
technology marketed by Camurus AB. Recently, Buvidal® (buprenorphine weekly or monthly) was
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approved in the European Union and Australia and tentatively approved in the United States (Brixadi™)
for the treatment of opioid use disorder [130,131]. The depot system is based on a phosphatidylcholine
and glyceroldioleate precursor solution which forms in situ a reversed non-lamellar liquid crystalline
structure with a tunable release profile [144,145]. Other products in di↵erent phases of clinical studies,
such as octreotide for the treatment of acromegaly and neuroendocrine tumors [119,132], leuprolide
for the treatment of prostate cancer, or setmelanotide for treating genetic obesity [120], demonstrate
the great potential of liquid crystalline phases as depot system.
Although the aqueous-based nanoemulsion developed by Rachmawati et al. does not show a
semi-solid behavior, it is discussed in this chapter since it relies on the same principle of dispersed
lipids in aqueous solutions [133]. Bupivacaine is distributed in castor oil droplets stabilized by
polymeric surfactants, as proven by cryo-transmission electron microscopy. Di↵erent biodegradable
oils and polymeric surfactants were evaluated for their potential as depot formulations but only
the nanoemulsion prepared with castor oil showed su cient stability over 3 months. The release
of bupivacaine was extended in vitro up to 24 h. Evaluating the in vivo plasma profile, the initial
burst release using the nanoemulsion was lowered in comparison to the bupivacaine solution, but the
nanoemulsion containing the same amount of bupivacaine as the control solution showed a lower
analgesic e↵ect than the bupivacaine solution (as explained by the slow release), and did not achieve
an e↵ective concentration. After increasing the concentration of drug in the nanoemulsion three times,
the analgesic e↵ect was then prolonged up to 24 h.
Classical organogels merely based on immobilized organic phase in a three-dimensional
network-building gelling agent undergo sol–gel transition in situ due to temperature increase or
because of partial desolvation [146]. Although in recent years major scientific e↵orts have been made
to expand the current portfolio of in situ forming systems, considered very attractive for their superior
clinical translational properties, some attempts to synthesize novel organogelators were successfully
carried out. For example, Li and coworkers synthesized a novel low-molecular-weight bis-amide
organogelator able to prolong the release of candesartan cilexetil out of a soybean organogel for up to
10 days in vivo with reasonably moderate inflammation at the injection site [134]. Newly synthesized
organogelators based on amino acid derivates induced a prolonged release in vitro of risperidone
out of soybean oil [135]. The depot e↵ect was confirmed in vivo, showing an almost linear release
behavior after s.c. injection over 8 days and suggesting a possible relevant translational potential, but a
comprehensive toxicity and biocompatibility study is missing.
6. Solid Particles and Implants
Solid drug delivery systems could be produced according to di↵erent technologies, each resulting
in products varying in size and structure.
Solid lipid implants are monolithic, typically cylindrical-shaped systems with diameter and length
in the millimeter range, whereas solid lipid nano- or microparticles are characterized by a size in the
nano- or micron-range, respectively, and both systems contain lipids or mixtures of them in a solid
state (Figure 5). To overcome the physical instabilities and the short shelf-life often associated with
solid lipid nanoparticles, nanostructured lipid carriers were introduced and are characterized by a less
ordered crystal structure due to the addition of liquid lipids to the solid lipids [147,148]. Surrounding
classical lipid cores with a phospholipid bilayer, lipospheres were created which were designed to
reduce the production costs of liposomes and improve their stability. The absence of an aqueous core
compared to liposomes limits the encapsulation of drugs to only lipophilic substances [149]. Despite
the fact that most often preparation requires the use of organic solvents, a method averting the use of
toxic organic solvents has been recently reported [150]. Furthermore, the solid lipid particles could be
merged with polymers to improve stability and encapsulation e ciency, and prolong the release rate.
An overview of reviewed solid lipid systems investigated in the last years is given in Table 5.
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Table 5. Overview of depot systems based on solid particles and implants.
Principle Encapsulated Drug Release Time Range Advantages (+) and Disadvantages (–) Ref.
Implants
Ovalbumin,
monoclonal antibody,
ranibizumab, insulin,
tumor peptide TRP2
Weeks in vitro
+ More versatile for lipophilic drugs
and biomacromolecules
+ No drug leakage during storage
+ No induced pH change for enhanced protein stability
– Injection with large needle diameter or surgery
– Non-biodegradable systems have to be removed
with surgery
– Foreign body reactions around monolithic system
[151,156–160]
Nanostructured lipid
carriers
Ondansetron Days in vitro andin vivo
+ Hydrophilic and lipophilic drugs
+ High stability with no crystallization of the lipid
– Use of organic solvents for preparation
– Relatively fast release due to small size and resulting
high surface
[161]
Core-shell systems of lipid
nano-/microparticles,
combinations with
polymers
Ropivacaine,
bupivacaine,
risperidone,
monoclonal antibody,
lysozyme, insulin
Days to weeks in vitro
and in vivo + Hydrophilic and lipophilic drugs, biomacromolecules
+ Prolonged release due to core–shell structure or
embedding in gel matrix
– Use of polymers with possible lower biocompatibility
– More steps during preparation required
[154,155,162–165]
Lipospheres or
nanostructured lipid
carriers in hydrogel
Quetiapine, estradiol
valerate
Hours to days in vitro
and in vivo [166,167]
Commonly marketed biodegradable implants based on the use of polymers such as PLGA produce
acidic degradation products which a↵ect the stability of proteins and peptides [168,169]. This drawback
could be overcome by usi g lipids for the form tion of implants: no pH change du ing storage takes
place and no burst release of the encapsulate drug is envisaged, thus providing enhanced stability of
proteins and peptides. Manufacturing of lipid implants by compression was the production method of
choice in the early stages of this technology because it was considered fast and uncomplicated [159,170].
Production is nowadays most commonly based on holt melt extrusion (also named solid lipid extrusion),
either in single- or twin-screw devices, a process that enables the achievement of a more sustained
release and homogenous drug distribution in comparison to other methods. Often-encapsulated
biologics are temperature-sensitive, so the lipid mixture must be carefully selected to ensure extrusion
at lowest possible temperatures [151,156–158,160]. Production by melting and casting lipid blends with
drugs is no longer state of the art since it employs higher temperatures than those used in extrusion
processes and could therefore cause instabilities in the APIs even faster [171,172]. General insights
Pharmaceutics 2020, 12, 0567 16 of 28
into the e↵ect of lipid composition and di↵erent preparation parameters on the physico-chemical
characteristics and the in vitro release behavior (up to 28 weeks) were obtained using albumin or
monoclonal antibodies as model proteins [156–158,160]. Lipid implants including a monoclonal
antibody from the IgG1 class and the fab-fragment ranibizumab showed a sustained release in vitro of
around 120 days with a good stability of the proteins, which were stabilized by cyclodextrines [151].
Overall, recent studies mainly focus on the preparation and characterization of the implants and do not
focus on the implementation in vivo and the drug release, pharmacokinetics, or pharmacodynamics.
An exception is represented by Even and coworkers, who showed in vivo results using the tumor
peptide TRP2 as an antigen in lipid implants [158]. The mice receiving this implant had a delayed
tumor growth of three days compared to control groups without TRP2 treatment. They explained this
low e↵ect with the slow release out of the implant and reported that this type of therapy might be not
appropriate for fast-growing tumors.
Solid lipid nano-/microparticles or nanostructured lipid carriers are not commonly used for
parenteral depot injectables owing to a relatively fast release caused by erosion of the particles,
a phenomenon that makes them ideal candidates predominantly for topical or oral administration
of drugs [161]. Nevertheless, they have been investigated as parenteral depot formulations.
Nanostructured lipid carriers encapsulating ondansetron were shown to enable an in vitro sustained
release up to 96 h, a result confirmed in vivo without the appearance of a burst release [161].
To prolong the release rate, hybrid systems of polymers and lipids were explored. Merging
poly-"-caprolactone nanoparticle cores with encapsulated ropivacaine and a lipid shell prolonged the
release of ropivacaine in vitro to 96 h [162]. The median duration of analgesia in vivo was maintained
over 36 h for the nanoparticles compared to 0.5 h for the plain ropivacaine solution. The same idea
was proposed by Ma and coworkers encapsulating bupivacaine into PLGA nanoparticles which were
surrounded by a lipid shell [165]. The hybrid system prolonged the in vitro release up to 96 h and,
in comparison to pure polymeric nanoparticles, the initial burst release was reduced. This observation
was confirmed in vivo with a 5-h extended analgesic e↵ect of the polymer–lipid hybrids over the
polymeric nanoparticles. The influence of di↵erent lipid types on core–shell particle systems was
demonstrated using mannitol microparticle cores with embedded monoclonal antibody IgG1 [163].
Glyceryl stearate as a coating showed an incomplete in vitro release of IgG1, whereas the release profile
was prolonged up to 6 weeks with increasing amounts of hard fat as the lipid shell and the initial
burst decreased.
Besides being used to create core–shell systems, lipids could also be included into the matrix of
polymeric systems with the aim of modulating the release profile of co-loaded drugs. For example,
encapsulating risperidone in PLGA microcapsules formulated with tuned middle-chain triglycerides
resulted in an almost ideal zero-order in vitro release kinetic over 60 days without the lag phase
typically observed for pure polymeric microparticles [155]. Imaging techniques suggest a multicore
inner structure of the microcapsules, with a core of dispersed lipid phase in which the drug could
be dissolved. To date, in vivo results to prove the concept are still lacking. The type of triglycerides
used to form hybrid particles has a major influence on the release behavior, as demonstrated by Wu
and coworkers [154]. The length of the acyl chain and the amount of lipid employed were correlated
with the initial burst release of lysozyme as the model protein; the longer the chain length the greater
the initial burst, and, as shown for one lipid, the burst release was increased by increasing the lipid
proportion from 33% to 67%. The amount of lipid influenced the encapsulation e ciency as well;
depending on the type of lipid the best results were achieved for lipid proportions between 5% and
20%, without a clear trend.
Analogous to the liposome-in gel-approach, lipid nanoparticles can be embedded in hydrogel
matrices to prolong the release of the encapsulated APIs. With the aim of creating a bio-shielding in situ
forming gel, quetiapine-loaded lipospheres were incorporated into a thermoresponsive gel composed
of Poloxamer® 407 [166]. Almost similar release profiles with a sustained release over three days
were achieved either with the lipospheres themselves or with the thermoresponsive gel containing
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lipospheres. However, in vivo studies presented almost no di↵erences in the AUC between the
lipospheres and the drug solution, but the presence of the thermoresponsive gel was crucial, protecting
the lipospheres against degradation by lipases and increasing the AUC threefold, demonstrating the
beneficial e↵ects of the combination of gel and lipospheres. Embedding nanostructured lipid carriers
containing estradiol valerate into a thermo-reversible hydrogel prolonged the release in vitro, with
only 20% of the drug released after 56 h [167]. The in vivo evaluation revealed a rapid initial release,
although the bioavailability was increased 17-fold and the tmax was delayed for 2 h in comparison to a
commercial drug suspension, showing the necessity for improvement to manipulate the release profile.
In summary, approaches proposed for solid long-acting formulations are very diverse and
range from nanoparticles to implants in the macro scale, demonstrating once again the versatility of
lipid-based technologies.
7. From Design to Application: Considerations about In Vitro Release Testing
In most of the new depot formulations discussed above, the in vitro release behavior of the drug
was tested as a first step to predict the in vivo performance and estimate the potential for clinical
applications. Medicine agencies worldwide have not issued any specific requirements for testing the
release from parenteral depot formulations yet, with only the standard dissolution apparatus from the
USP or the Ph. Eur. being mentioned. A team from the FDA recently addressed the variations in the
release behavior among the standard methods, and even for a marketed formulation like Exparel a
consensus on standard in vitro release test is missing [173]. Completely di↵erent release profiles for
bupivacaine-loaded multivesicular liposomes were obtained using a sample and separation method
or a reverse dialysis method, and temperature and agitation speed modulated the release profile.
Presumably similar results would be obtained by testing more drug delivery systems, demonstrating
that the choice of in vitro release setup as well the used media have a great influence on the results and
should be carefully chosen.
To date it is unclear if a release study in a bulk fluid dissolution set up under sink conditions could
reflect and predict in vivo behavior, since the injection sites in s.c. or i.m. administrations have di↵erent
hydrodynamics, generally low volumes of body fluids, and various possibilities for interaction with the
depot delivery system. Choosing an appropriate in vitro release method mimicking the physiological
conditions of the injection site could improve the correlation to the in vivo release. We believe that
there is a lack in transferring standard release methods specified by USP or Ph. Eur. to ones which are
closer to physiological conditions.
For mimicking the extracellular matrix (a major component of the subcutaneous tissue), employing
hydrogels appears to be the most straightforward and simple approach to simulating in vivo conditions.
Agarose is usually used due to its similar porosity and water content to soft tissue [174,175], as well
gelatin [137,176]. This approach could be combined with UV–VIS imaging techniques or laser-induced
breakdown spectroscopy to detect the real-time release of drugs and to give provide an exhaustive
insight in the release behavior [159,177,178]. The company Pion claims to have developed a device
simulating the stress conditions and environmental transitions that a↵ect a drug after s.c. injection,
proposing thus a more complex approach with respect to the basic use of a hydrogel matrix [179,180].
The Subcutaneous Injection Site Simulator (Scissor) is composed of a modified dialysis chamber filled
with hyaluronic acid to mimic the extracellular matrix, which is immersed in a carbonate bu↵er. Several
parameters are tracked during the in vitro release to detect interactions with the matrix. Although this
system is intended for biopharmaceuticals it could be also useful for other long-acting injectables and
depot formulations. More complex in vitro release setups including adipose tissue could be achieved
by using skin for release tests. Especially for lipid-based depot formulations, possible interactions
with the fat tissue are conceivable. The company Genoskin developed a method to keep human skin
biopsies alive for seven days [181]. HypoSkin® contains all three layers of the skin and is intended
for s.c. injections, aiming to get a better understanding of the release mechanism, degradation rate,
and in vivo behavior.
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Although some of the developed methods have been described only for polymeric systems,
it is envisaged that these release assays could be adapted to any kind of depot system. The use of
physiological setups for in vitro release studies could give a better prediction of in vivo behavior,
and may open up possible optimizations of drug delivery systems before proceeding into in vivo
studies, thus reducing, replacing, and refining the animal studies according to the 3R concept of
Russell and Burch [182]. Ideally, not only the physiological conditions at the injection site should be
mimicked, but also possible side e↵ects, like an inflammatory response leading to an increase in the
blood circulation and a change in the pH value. In the long-term, the building of a fibrotic capsule
should be taken into account.
8. Conclusions
Depot formulations are an attractive way to administer drugs, with a reduced dosing frequency
and a simultaneous improvement of therapeutic e cacy and compliance of patients. Starting with
the oldest approach of oily solution for i.m. injection in the 1950s, the continuous and successful
development of novel concepts has demonstrated that lipid-based long-acting injectables represent
a versatile technology. The whole range of drugs, from small molecules to biomacromolecules like
proteins, peptides, and antibodies can be encapsulated thanks to the unique properties of lipids.
The increasing number of approved biologics has called for the development of new parenteral drug
delivery systems. In particular, in situ forming systems like liquid crystalline depots or phospholipid
phase separation gels, liposomes, and implants are used for this purpose. Overall, the two most
successful approaches for lipid-based depot formulations are multivesicular liposomes (DepoFoam
technology) and liquid crystalline phases (FluidCrystal technology). Products such as Exparel and
Buvidal, respectively, are remarkable commercial successes stemming from those depot systems.
The two platforms have generated an enthusiastic consensus in the drug delivery community, and an
increasing number of research groups are attempting to bring the two concepts a step further, extending
the recommended applications or loading novel APIs. A plethora of other long-acting systems have
undergone constant further development in recent years, proving their suitability in several in vivo
studies, and these will likely be tested in clinical studies in the future. Thanks to new and improved
analytical methods it is nowadays possible to visualize the release of drugs and the degradation of the
delivery system in vitro and in vivo, enabling the collection of useful information about the systems
for further development. Using optimized in vitro release setups mimicking physiological conditions,
a better prediction about the in vivo behavior could be obtained.
A universal depot system able to encapsulate any drug, with a tunable release, no toxicity,
an easy and inexpensive manufacturing process, and long-term stability remains a Holy Grail in
drug delivery. Lipids stand out from other excipients formulating long-acting systems due to their
unbeatable biocompatibility and safety profile, especially phospholipids which lack toxicity thanks to
their physiological presence. Besides representing an ideal building block for optimal sustained-release
platforms of APIs, lipids succeed in enhancing the solubility of poorly water-soluble drugs, in increasing
their stability, and in protecting them from degradation, improving their bioavailability overall.
From the multitude of lipid-based technologies nowadays available, the most appropriate delivery
system for the API to be delivered to treat a specific medical condition can always be identified.
The versatility of the lipid excipients can duly ensure further customization, ultimately resulting in a
safe injectable depot with an optimal long-acting drug release over a duration of days to weeks.
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